TARGET Study Demonstrates Sustained Performance and Favorable Safety Profile of the Cardiovalve TR System in High-Risk Patients with Severe Tricuspid Regurgitation
Late-breaking 6-month full cohort data presented at PCR London Valves 2026 shows durable tricuspid regurgitation reduction up to 3 years, positive right heart remodeling and quality-of-life improvements, as the company advances its CE Mark application. LONDON, Nov. 22, 2026 /PRNewswire/...
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


